OMER Share Price | Omeros Corp. Stock Analysis & Recommendation

Q: What does Omeros Corp. do?

Overview:Omeros Corporation is a commercial-stage biopharmaceutical company engaged in discovering, developing, and commercializing therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -38 Million (Quarterly Results - Mar 2025)Market cap: USD 188.08 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Dividend Yield: 0.00%Debt Equity: -1.64Return on Equity: 82.58%Price to Book: -0.88Contact Details:Address: 201 Elliott Ave W, SEATTLE WA: 98119-4240Tel: 1 206 6765000Website: http://www.omeros.com

Q: Who are in the management team of Omeros Corp.?

As of March 2022, the management team of Omeros Corp. includes Dr. Gregory Demopulos, who serves as the Chairman of the Board, President, and Chief Executive Officer. The board also features Mr. Thomas Cable as the Lead Independent Director, along with Dr. Peter Demopulos, Mr. Ray Aspiri, Dr. Thomas Bumol, and Mr. Arnold Hanish, all serving as Independent Directors.

Q: Is Omeros Corp. overvalued or undervalued?

As of 9 November 2022, Omeros Corp. moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently overvalued, as evidenced by its negative Price to Book Value of -1.03 and an EV to EBIT ratio of -3.46, which highlight its financial struggles. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -120.45%, further underscoring the company's challenges in generating returns.In comparison to its peers, Omeros Corp. significantly lags behind Rigel Pharmaceuticals, which has a P/E ratio of 9.21 and an EV to EBITDA of 7.02, indicating a much healthier valuation. Other peers like Astria Therapeutics and Merrimack Pharmaceuticals also show negative metrics, but none approach the extreme negative ratios seen with Omeros. The company's recent stock performance, with a year-to-date decline of 67.71% compared to a modest 2.44% gain in the S&P 500, reinforces the notion that Omeros is not only struggling but also overvalued in the current market context.

Q: Is Omeros Corp. technically bullish or bearish?

As of 25 August 2025, the technical trend for Omeros Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD and KST are mildly bullish, the overall indicators suggest a lack of strength in the bullish direction. In terms of performance, Omeros has underperformed the S&P 500 significantly year-to-date, with a return of -56.88% compared to the S&P's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

246.85 k

Shareholding (Dec 2025)

FII

5.42%

Held by 44 FIIs

DII

80.68%

Held by 17 DIIs

Promoter

0.00%

How big is Omeros Corp.?

22-Jun-2025

As of Jun 18, Omeros Corp. has a market capitalization of 188.08 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -176.33 million over the last four quarters. The balance sheet as of Dec'24 shows shareholder's funds of -182.61 million and total assets of 277.08 million.

View full answer

What does Omeros Corp. do?

22-Jun-2025

Omeros Corporation is a biopharmaceutical company focused on developing therapeutics for inflammation, complement-mediated diseases, and central nervous system disorders. It has a market cap of $188.08 million and reported a net profit loss of $38 million as of March 2025.

View full answer

Who are in the management team of Omeros Corp.?

22-Jun-2025

As of March 2022, Omeros Corp.'s management team includes Dr. Gregory Demopulos as Chairman, President, and CEO, with Mr. Thomas Cable as Lead Independent Director and several Independent Directors: Dr. Peter Demopulos, Mr. Ray Aspiri, Dr. Thomas Bumol, and Mr. Arnold Hanish.

View full answer

Is Omeros Corp. overvalued or undervalued?

25-Jun-2025

As of November 9, 2022, Omeros Corp. is overvalued with a negative Price to Book Value of -1.03 and a troubling ROCE of -120.45%, significantly lagging behind peers like Rigel Pharmaceuticals, and has seen a year-to-date stock decline of 67.71%.

View full answer

Is Omeros Corp. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Omeros Corp. is in a mildly bearish trend, with daily moving averages and weekly RSI indicating bearish momentum, while year-to-date performance shows a significant underperformance of -56.88% compared to the S&P 500's 12.22%.

View full answer

Compare Omeros Corp. with Similar Stocks

Merrimack Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.PolyPid Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 790 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.44

Return on Equity

53.36%

Price to Book

-3.58

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

80 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

30.37%

6 Months

122.15%

1 Year

130.55%

2 Years

302.2%

3 Years

185.94%

4 Years

396.27%

5 Years

-17.52%

Omeros Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-6.55%

EBIT to Interest (avg)

-6.13

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.64

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-3.58

EV to EBIT

-8.57

EV to EBITDA

-8.64

EV to Capital Employed

11.31

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-131.97%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 30 Schemes (13.9%)

Foreign Institutions

Held by 44 Foreign Institutions (5.42%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 476.89% vs 18.15% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.80",
          "val2": "-26.20",
          "chgp": "-9.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.70",
          "val2": "-13.40",
          "chgp": "164.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-119.00",
          "val2": "-8.80",
          "chgp": "-1,252.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "79.90",
          "val2": "-21.20",
          "chgp": "476.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 97.37% vs -4.40% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-121.80",
          "val2": "-168.30",
          "chgp": "27.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "24.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-122.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-182.60",
          "chgp": "97.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.80

-26.20

-9.92%

Interest

8.70

-13.40

164.93%

Exceptional Items

-119.00

-8.80

-1,252.27%

Consolidate Net Profit

79.90

-21.20

476.89%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 476.89% vs 18.15% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-121.80

-168.30

27.63%

Interest

0.00

24.70

-100.00%

Exceptional Items

-122.70

0.00

Consolidate Net Profit

-4.80

-182.60

97.37%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 97.37% vs -4.40% in Dec 2024

All Annual Results

Company CV

About Omeros Corp.

Omeros Corp.

Pharmaceuticals & Biotechnology

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Company Coordinates

Company Details

201 Elliott Ave W , SEATTLE WA : 98119-4240

Tel: 1 206 6765000

http://www.omeros.com

Registrar Details